TY - JOUR
T1 - Diagnosis and treatment of iron deficiency in chronic heart failure
T2 - Position statement of the heart failure working group of the Austrian Society of Cardiology
AU - Heart Failure Working Group of The Austrian Society for Cardiology
AU - Messner, Moritz
AU - Pölzl, Gerhard
AU - Adlbrecht, Christopher
AU - Altenberger, Johann
AU - Auer, Johann
AU - Berent, Robert
AU - Dörler, Jakob
AU - Zaruba, Marc-Michael
AU - Ebner, Christian
AU - Fruhwald, Friedrich
AU - Hülsmann, Martin
AU - Mörtl, Deddo
AU - Rainer, Peter P
AU - Rab, Anna
AU - Weber, Thomas
AU - Berger, Rudolf
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/3
Y1 - 2025/3
N2 - Iron deficiency (ID) is a common comorbidity in heart failure (HF), affecting 55% of chronic and up to 80% of acute HF patients, regardless of ejection fraction (EF). An ID is associated with reduced quality of life, impaired exercise capacity (VO2 peak), higher hospitalization rate and lower survival rate. It is also an independent predictor of HF outcomes. This consensus statement critically reviews the diagnostic criteria for ID in HF and provides recommendations for their use. The efficacy and safety of intravenous iron supplements, including ferric carboxymaltose (FCM) and ferric derisomaltose (FDI), are analyzed highlighting the indications and potential adverse effects. Key clinical trials and guideline recommendations are summarized. In summary, the document addresses the diagnostics, treatment and monitoring of ID in HF.
AB - Iron deficiency (ID) is a common comorbidity in heart failure (HF), affecting 55% of chronic and up to 80% of acute HF patients, regardless of ejection fraction (EF). An ID is associated with reduced quality of life, impaired exercise capacity (VO2 peak), higher hospitalization rate and lower survival rate. It is also an independent predictor of HF outcomes. This consensus statement critically reviews the diagnostic criteria for ID in HF and provides recommendations for their use. The efficacy and safety of intravenous iron supplements, including ferric carboxymaltose (FCM) and ferric derisomaltose (FDI), are analyzed highlighting the indications and potential adverse effects. Key clinical trials and guideline recommendations are summarized. In summary, the document addresses the diagnostics, treatment and monitoring of ID in HF.
KW - Humans
KW - Heart Failure/diagnosis
KW - Anemia, Iron-Deficiency/diagnosis
KW - Austria
KW - Chronic Disease
KW - Cardiology/standards
KW - Practice Guidelines as Topic
KW - Maltose/analogs & derivatives
UR - http://www.scopus.com/inward/record.url?scp=105004578575&partnerID=8YFLogxK
U2 - 10.1007/s00508-025-02521-x
DO - 10.1007/s00508-025-02521-x
M3 - Journal article
C2 - 40327072
SN - 1613-7671
VL - 137
SP - 143
EP - 156
JO - Wiener Klinische Wochenschrift. The Central European Journal of Medicine
JF - Wiener Klinische Wochenschrift. The Central European Journal of Medicine
IS - Suppl 3
ER -